Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7608282 | KYOWA KIRIN | Transdermal granisetron |
Jan, 2025
(1 year, 11 months from now) |
Market Authorisation Date: 12 September, 2008
Treatment: Use of granisetron transdermal system to treat/prevent chemotherapy induced nausea and vomiting
Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8252304 | HERON THERAPS INC | Semi-solid delivery vehicle and pharmaceutical compositions for delivery of granisetron |
Sep, 2024
(1 year, 7 months from now) | |
US8715710 | HERON THERAPS INC | Semi-solid delivery vehicle and pharmaceutical compositions for delivery of granisetron |
Sep, 2024
(1 year, 7 months from now) | |
US10357570 | HERON THERAPS INC | Methods of treating nausea utilizing semi-solid delivery vehicle compositions comprising granisetron |
Sep, 2024
(1 year, 7 months from now) | |
US8252305 | HERON THERAPS INC | Methods of treating emesis utilizing semi-solid delivery pharmaceutical compositions comprising granisetron |
Sep, 2024
(1 year, 7 months from now) | |
US9913910 | HERON THERAPS INC | Methods of treating nausea utilizing semi-solid delivery vehicle compositions comprising granisetron |
Sep, 2024
(1 year, 7 months from now) |
Market Authorisation Date: 09 August, 2016
Treatment: Prophylactic treatment of nausea and vomiting, including prevention of acute and delayed nausea and vomiting associated chemotherapy; Treatment or prevention of nausea and vomiting
Dosage: INJECTION, EXTENDED RELEASE;SUBCUTANEOUS
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic